Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Obama calls for rapid Zika research as virus seen spreading

President Barack Obama on Tuesday called for the rapid development of tests, vaccines and treatments to fight the mosquito-transmitted Zika virus, which has been linked to birth defects and could spread to the United States in warmer months. U.S. health officials are stepping up efforts to study the link between Zika virus infections and birth […]

Read More »

Major drugmakers push back in U.S. price debate

With a backlash brewing over the price of medicines in the United States, drugmakers are pushing back with a new message: Most people don’t pay retail.    Top executives from Eli Lilly and Co (LLY.N), Merck & Co (MRK.N) and Biogen Inc (BIIB.O) said in interviews with Reuters this week that the media focus on retail, […]

Read More »

U.S. justices reject Johnson & Johnson unit’s anti-psychotic drug appeal

The U.S. Supreme Court on Monday declined to hear a Johnson & Johnson subsidiary’s appeal of a $124 million penalty imposed by South Carolina after a jury found the drugmaker had improperly marketed the anti-psychotic drug Risperdal and concealed its risks. The court’s decision not to hear the appeal filed by Johnson & Johnson’s Janssen […]

Read More »

Eli Lilly’s diabetes pill takes market share from J&J, Astra

Eli Lilly and Co’s new Jardiance diabetes treatment has begun stealing market share from rival drugs in its class, the company said on Tuesday, bolstered by clinical trial data showing it slashed deaths by 32 percent in patients with Type 2 diabetes. In a three-year study whose results were released last summer, Jardiance became the […]

Read More »

Actelion sees Uptravi price of $160,000-170,000/patient

Swiss drug company Actelion expects an average annual per-patient price for its new pulmonary arterial hypertension medicine in the United States of $160,000 to $170,000, before rebates, Chief Operating Officer Otto Schwarz told analysts on Tuesday.   The drug, Uptravi, won approval from the U.S. Food and Drug Administration last month and went on sale […]

Read More »

Sanofi pulls plug on MannKind inhaled insulin after poor sales

French drugmaker Sanofi is to stop selling an inhalable insulin developed by MannKind, following disappointing sales of the product since its launch in February 2015. The decision to terminate the collaboration marks a blow for the idea of delivering insulin through an inhaler, rather than by injection, and shares in U.S.-based MannKind were down around […]

Read More »

Drug approvals at 19-year high belie industry challenges

2015 was a good year for innovation in medicine with the U.S. Food and Drug Administration approving 45 novel drugs, four more than in 2014 and the most since the all-time record of 53 set in 1996. Across the Atlantic, the European Medicines Agency recommended 93 new products, including generics, up from 82 in 2014. […]

Read More »

Mylan Launches Generic Zyvox Tablets

HERTFORDSHIRE, England and PITTSBURGH, Dec. 29, 2015 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer’s Zyvox® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which […]

Read More »

Celgene settles U.S. patent litigation for top seller Revlimid

Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire. The company said it would provide India-based Natco Pharma Ltd and its U.S. partner, Arrow International Limited, a unit of Allergan Plc, […]

Read More »

Bristol’s drug pricing under fire as UK agency rejects Opdivo

Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog. In draft guidance issued on Wednesday, the National Institute for Health and Care Excellence (NICE) said using Opdivo, […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom